Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BVAXF Relative to the S&P 500

Seasonal Chart Analysis

Analysis of the BioVaxys Technology Corp. (OTCMKT:BVAXF) seasonal charts above shows that a Buy Date of August 10 and a Sell Date of November 2 has resulted in a geometric average return of 39.71% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 63.7% per year.

A word of caution: Only 6 years of data is available for shares of BVAXF, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix ?neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix ?neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

To download BVAXF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BVAXF